Mustang Bio Key Fundamental And Technical Indicators

Stocks USA . 
Stock . Mustang Bio
MBIO Stock  USD 0.70  -0.03  -4.11%   
Mustang Bio's key ratios are summarized here so margins, returns, and balance-sheet strength can be compared at a glance. The current ratio is 9.96, showing the ability to cover short-term obligations. Certain ratio combinations -- such as high leverage with low interest coverage -- are traditionally watched as stress markers. Based on the latest data, the 14-period RSI for Mustang Bio is 0, signaling extreme oversold conditions. Readings below 20 are commonly associated with potential stabilization zones.
Momentum
OversoldOverbought
0 · Capitulated
As of the 10th of May, shares of Mustang Bio change hands at 0.70 per share. Momentum and volatility readings indicate Downside Deviation of 3.37, mean deviation of 2.68, and Risk Adjusted Performance of 0.0231. The system measures statistical relationships between price fluctuations and trading activity. Under $1.00, bid-ask spread dynamics carry greater weight. Indicator values are assessed relative to historical performance bands.
Cycles Operators Shifting Impulse Patterns Depth Overlaps Statistics Volatility Volume
A thorough review of Mustang Bio's financial statements uncovers patterns in revenue and profitability. Core fundamentals used to assess intrinsic value are listed below: Mustang Bio's financial disclosures separate accounting earnings from economic reality. Key fundamentals are provided below:
 Market Capitalization
5.27 million
 Revenue
-50,000
 Earnings Share
-0.39
 Revenue Per Share
-0.002
Across one hundred twenty fundamental ratios, Mustang Bio offers a broad dataset for trend analysis and peer comparison. It may be useful to review Mustang Bio's up-to-date fundamental drivers against all of the trends between 2010 and 2026. Using the latest reported data from December 31, 2025, Market Cap is holding steady around $48.15 million. In addition to that, Enterprise Value is holding steady around $30.88 million. For custom fundamental screens that go beyond Mustang Bio, explore the full Equity Screeners suite.
Altman
Z Score
Details
Piotroski
F Score
Details
Beneish
M Score
Details
Profitability
Analysis
Details
Earnings
Projections
Details

Balance Sheet Accounts

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Short and Long Term Debt Total$959,215$1.01 million6.4 M
High Variability
Other Current Liabilities$4.93 million$4.25 million3.4 M
Moderate Growth
Total Current Liabilities$9.57 million$7.91 million7.4 M
Moderate Growth
Accounts Payable$3.86 million$3.51 million2.5 M
Moderate Growth
Common Stock Total Equity$8,452.5$8,0504.1 K
Consistent Growth
Common Stock Shares Outstanding51.54 million49.08 million8.4 M
Moderate Growth
Non Current Liabilities Total$142,500$150,0004.4 M
High Variability
Capital Surplus$333.23 million$317.36 million144.3 M
Consistent Growth
Other Stockholder Equity$263.05 million$407.9 million170.3 M
Consistent Growth
Total Liabilities$14.84 million$8.06 million10.8 M
High Variability
Short and Long Term Debt$1.37 million$1.12 million2 M
Moderate Decline
Short Term Debt$761,200$410,4001.7 M
Consistent Decline
Common Stock$950$1,0003.1 K
High Variability
Total Assets$16.71 million$17.59 million44.8 M
High Variability
Cash$16.4 million$17.27 million37.4 M
High Variability
Cash And Short Term Investments$16.4 million$17.27 million39.9 M
High Variability
Liabilities And Stockholders Equity$16.71 million$17.59 million44.8 M
High Variability
Total Current Assets$16.71 million$17.59 million41 M
High Variability
Accumulated Other Comprehensive Income$259,350$273,0003.7 M
High Variability
Other Liabilities$366,025$310,500202.2 K
Moderate Growth
Net Receivables$206,150$217,000351.3 K
High Variability
Other Current Assets$104,500$110,000860.7 K
High Variability
Capital Stock$950$1,0003.9 K
High Variability
Non Current Liabilities Other$1.66 million$2.24 million1.3 M
Consistent Growth
Long Term Debt Total$9.74 million$10.96 million12 M
Stable

Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Interest Expense$5,462.5$5,750738.8 K
High Variability
Selling General Administrative$3.75 million$3.95 million5.1 M
Moderate Growth
Other Operating Expenses$2.31 million$2.43 million24.6 M
High Variability
Research Development$1.44 million$1.52 million19.3 M
High Variability
Total Operating Expenses$2.27 million$2.39 million24 M
High Variability
Interest Income$644,930$511,000388.5 K
Moderate Growth
Non Recurring$8.41 million$11.57 million7.9 M
Moderate Growth
Reconciled Depreciation$38,950$41,000749.1 K
High Variability
Selling And Marketing Expenses$292,000$328,500358.6 K
Stable

Cash Flow Statement Items

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Sale Purchase Of Stock$789,165$830,70020.1 M
Moderate Decline
Depreciation$38,950$41,000721.4 K
High Variability
Change To Netincome$9.71 million$12.69 million7.7 M
Moderate Growth
Cash Flows Other Operating$10.41 million$18.18 million10.6 M
Moderate Growth
End Period Cash Flow$16.4 million$17.27 million37.7 M
High Variability
Begin Period Cash Flow$6.5 million$6.84 million37.7 M
High Variability

Financial Ratios

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Dividend Yield0.93%0.57%0.0108
Moderate Variation
Capex To Depreciation$0.06$0.06660
Consistent Decline
Payables Turnover0.010.010.1874
High Variability
Cash Per Share0.330.3514.7589
High Variability
Days Payables Outstanding29,528.9528,122.85.7 K
Moderate Growth
Income Quality$2.88$2.740.8103
Moderate Growth
Current Ratio2.112.227.2264
Moderate Decline
Capex Per Share0.010.021.2904
Moderate Decline
Interest-Bearing Debt Per Share0.160.142.9272
Moderate Decline
Debt To Assets0.1x0.08x0.0887
High Variability
Days Of Payables Outstanding29,528.9528,122.85.7 K
Moderate Growth
Long Term Debt To Capitalization0.22x0.33x0.2541
Moderate Growth
Quick Ratio2.112.227.2264
Moderate Decline
Net Income Per EBT$0.83$0.931.0195
Stable
Cash Ratio2.072.186.5216
Moderate Decline
Free Cash Flow Operating Cash Flow Ratio1.251.151.1719
Stable
Debt Ratio0.10.080.0887
High Variability

Valuation Indicators

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Market Cap$45.74 million$48.15 million6.7 B
Consistent Decline
Enterprise Value$29.34 million$30.88 million6.6 B
Consistent Decline

Core Fundamental Drivers

Return On Asset TTM Driver Correlations

The correlation data quantifies how Return On Asset TTM at Mustang Bio relates to other financial line items. These relationships describe association across reporting periods, not causation.
Click cells to compare fundamentals
Competition

Mustang Bio Accumulated Other Comprehensive Income

Accumulated Other Comprehensive Income

$259,350
Accumulated Other Comprehensive Income stood at $273,000 as of December 31, 2025.

Mustang Bio Fundamental Drivers Relationships

ROE stood at -0.21 as of December 31, 2025. Related reported metric: Return On Asset TTM at -11.00% as of December 31, 2025.

Main Technical Indicators as of May 10, 2026

Cycle Indicators
Math Operators
Math Transform
Momentum Indicators
Overlap Studies
Pattern Recognition
Price Transform
Statistic Functions
Volatility Indicators
Volume Indicators
Risk Adjusted Performance0.0231
Market Risk Adjusted Performance-0.25
Mean Deviation2.68
Semi Deviation2.85
Downside Deviation3.37
Coefficient Of Variation5841.27
Standard Deviation3.53
Variance12.49
Information Ratio0.0206
Jensen Alpha0.0461
Total Risk Alpha0.1368
Sortino Ratio0.0216
Treynor Ratio-0.26
Maximum Drawdown16.67
Value At Risk-4.95
Potential Upside6.94
Downside Variance11.38
Semi Variance8.11
Expected Short fall-3.46
Skewness0.7716
Kurtosis0.8111

Daily Market Strength Indicators

Market strength indicators for Mustang Bio stock provide a framework for assessing security responsiveness. A rising Accumulation/Distribution line alongside rising price confirms institutional buying interest in Mustang Bio. Median and Typical Price smooth out intraday extremes, providing a cleaner reference level for evaluating Mustang Bio sessions. Persistent divergence between momentum indicators and price often precedes trend reversals in Mustang Bio.
Accumulation Distribution0.0556
Daily Balance Of Power-0.75
Rate Of Daily Change0.96
Day Median Price0.7
Day Typical Price0.7
Market Facilitation Index0.04
Price Action Indicator-0.01
Period Momentum Indicator-0.03

Basic Forecasting Models

The distribution of Mustang Bio's daily returns is typically non-normal, with fatter tails than a Gaussian model predicts. This reveals hidden support and resistance zones in Mustang Bio's chart that simple price charts miss. The slope of Mustang Bio's linear regression channel quantifies trend direction and strength over a chosen lookback period. Divergences between OBV and price foreshadow trend changes in Mustang Bio.
Naive Prediction
Simple Exponential Smoothing
Double Exponential Smoothing
Triple Exponential Smoothing
Simple Regression
Polynomial Regression
Simple Moving Average
4 Period Moving Average
8 Period Moving Average
20 Period Moving Average

Mustang Bio Related Equities

The peer firms below within the Health Care space frame Mustang Bio's pricing and running costs in context. Looking at Mustang Bio's pricing multiples next to these peers shows if the stock trades at a premium or discount. Persistent outperformance or underperformance by specific peers relative to Mustang Bio often signals structural advantages or weaknesses. This type of review is most informative when done often to track how positions shift over time.
 Risk & Return  Correlation

Return On Asset TTM Peer Comparison

Comparing Mustang Bio's Return On Asset TTM to that of its competitors is a reliable method for assessing relative value. Comparing Mustang Bio's Return On Asset TTM to peer stocks determines whether it trades at a premium or discount. Tracking Mustang Bio's Return On Asset TTM rank within the peer group over time reveals shifts in competitive dynamics. The Return On Asset TTM peer framework provides a practical lens for evaluating Mustang Bio's relative standing.
Mustang Bio is currently under evaluation in return on asset ttm compared to key competitors.

Important Fundamentals

Return On Equity TTM-0.45
Return On Asset TTM-0.13
Current Valuation-12.04 M
Shares Outstanding6.73 M
Shares Owned By Insiders4.29 %
Shares Owned By Institutions10.92 %
Number Of Shares Shorted101.08 K
Price To Earnings TTM-11.40 X
Price To Book TTM0.55 X
Price To Sales TTM2,206 X
EBITDA TTM-2.39 M
Net Income TTM-1.92 M
Cash And Equivalents TTM107.37 M
Cash Per Share TTM1.01 X
Total Debt TTM8.06 M
Debt To Equity TTM0.35 %
Current Ratio TTM9.96 X
Book Value Per Share TTM1.31 X
Cash Flow From Operations TTM-5.26 M
Short Ratio TTM2.77 X
Earnings Per Share-0.39 X
Target Price10.0
Trailing Beta2.11
Market Capitalization TTM5.27 M
Total Asset TTM17.59 M
Retained Earnings TTM-398.64 M
Working Capital TTM9.68 M
Current Asset TTM42.37 M
Current Liabilities TTM3.93 M
Net Asset17.59 M

Financial Metrics, Fundamentals & Methodology

A financial review of Mustang Bio starts with revenue scale, margin durability, and liquidity flexibility. Operating margins help show whether the business still holds structural pricing or cost advantages. For the latest reporting period, Mustang Bio reports EPS loss of 0.39, current ratio of 9.96, debt-to-equity of 0.35.

Mustang Bio inputs come from periodic company reporting and market reference feeds and are mapped into a consistent reporting framework. Reported income, balance-sheet, and cash-flow fields adhere to GAAP or IFRS presentation rules.

Editorial review and methodology oversight provided by: Michael Smolkin, Member of Macroaxis Board of Directors


 
Tools
Analysis
Directory
Company
2026 Macroaxis LLC Made with in San Francisco
Privacy Terms Widgets Feedback
Macroaxis is not a registered investment advisor or broker/dealer. All investments, including stocks, funds, ETFs, or cryptocurrencies, are speculative and involve substantial risk of loss. We encourage our investors to invest carefully. Much of our information is derived directly from data published by companies or submitted to governmental agencies which we believe are reliable, but are without our independent verification. Therefore, we cannot assure you that the information is accurate or complete. We do not in any way warrant or guarantee the success of any action you take in reliance on our statements or recommendations. Also, note that past performance is not necessarily indicative of future results. All investments carry risk, and all investment decisions of an individual remain the responsibility of that individual. There is no guarantee that systems, indicators, or signals will result in profits or that they will not result in losses. All investors are advised to fully understand all risks associated with any investing they choose to do. Hypothetical or simulated performance is not indicative of future results. We make no representations or warranties that any investor will, or is likely to, achieve profits similar to those shown because hypothetical or simulated performance is not necessarily indicative of future results. For more information please visit our terms and conditions page.